Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether intratracheal administration of budesonide
combined with surfactant, as compared to surfactant alone, will modify ecographic (lung
ultrasound score) and biological markers (IL-6 concentration in respiratory secretions) at 7
days of life in preterm infants ≤32 weeks of gestational age (GA).